Collagenase clostridium histolyticum for Peyronie's disease: A new minimally invasive and effective treatment.
- Author:
Hao-Cheng LIN
1
;
Hai-Tao ZHANG
1
;
Hui JIANG
1
Author Information
1. Department of Urology, Peking University Third Hospital, Beijing 100191, China .
- Publication Type:Journal Article
- Keywords:
collagenase clostridium histolyticum;
efficacy;
safety;
treatment;
Peyronie's disease
- MeSH:
Erectile Dysfunction;
etiology;
Humans;
Injections, Intralesional;
Male;
Microbial Collagenase;
therapeutic use;
Penile Induration;
drug therapy;
surgery;
Penis;
Postoperative Complications;
etiology;
Treatment Outcome
- From:
National Journal of Andrology
2017;23(9):771-775
- CountryChina
- Language:Chinese
-
Abstract:
The treatment of Peyronie's disease has been a challenge to urologists, as most of the current oral medications are considered hardly valid and the rest of the therapies require strict control of indications, some of which remain controversial, while the final surgical option may be associated with complications such as penile shortening or erectile dysfunction. Collagenase clostridium histolyticum has been proved to be effective in dissolving the penile cavernosal plaque and approved by the Food and Drug Administration of the USA as the first drug to be used for the treatment of Peyronie's disease. This article presents an introduction to the characteristics, safety, efficacy, and procedures of this new treatment, which may benefit urologists and the patients with Peyronie's disease.
